Download PDF
Arzneimittelforschung 2011; 61(5): 312-316
DOI: 10.1055/s-0031-1296204
Analgesics · Anti-inflammatories · Antiphlogistics · Antirheumatic Drugs
Editio Cantor Verlag Aulendorf (Germany)

Risk of hepatotoxicity with add-on leflunomide in rheumatoid arthritis patients

Rachna Gupta
1   Department of Pharmacology, University College of Medical Sciences, Guru Tegh Bahadur (GTB) Hospital, New Delhi, India
,
Jagriti Bhatia
2   Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
,
Suresh Kumar Gupta
2   Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations
Further Information

Publication History

Publication Date:
27 November 2011 (online)

    Permissions and Reprints

Abstract

Combination of disease-modifying antirheumatic drugs (DMARDs) is increasingly used in the treatment of rheumatoid arthritis (RA) patients. Hepatotoxicity has been an important safety concern with DMARDs therapy. Though leflunomide (CAS 75706-12-6) has emerged as an effective oral DMARD, its use is associated with hepatotoxicity. Limited data is available regarding hepatotoxic risk when leflunomide is used in combination therapy in RA patients. An open-label, prospective study was conducted to evaluate the hepatotoxic risk after addition of leflunomide with other DMARDs in RA patients, who did not respond to their ongoing DMARD therapy. A total of 46 patients were enrolled and leflunomide was given as add-on therapy with earlier DMARDs. Biochemical parameters of serum aminotransferase levels (AST and ALT) were estimated at the baseline and then every month after addition of leflunomide. Study results showed that 13.0% patients developed <1.5 to <2 times upper limit of normal (ULN) elevation; 6.5%patients developed 2 to <3 times the ULN elevation and 2.2% patients developed >3 times the ULN elevation. In 20% of the patients with hepatic enzyme elevations, enzyme levels returned to normal within 4–6 weeks after discontinuation of leflunomide therapy, whereas in 50% of patients the dose of leflunomide was reduced from 20 mg/day to 10 mg/day for normalization of enzymes levels. 30% of patients were continued with leflunomide without dose reduction. None of the patients showed clinical signs and symptoms of hepatotoxicity. Leflunomide therapy with other DMARDs requires strict monitoring of serum aminotransferases.

Key words

Add-on therapy - Disease-modifying antirheumatic drugs - Hepatotoxicity - Leflunomide - Rheumatoid arthritis
 

  • References

  • 1 Quinn MA, Conaghan PG, Emery P.. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?. Rheumatology 2001; 40 (11) 1211-20
    CrossrefPubMedSearch in Google Scholar
  • 2 Lard LR, Visser H, Speyer I, van der Horst-Bruinsma IE, Zwinderman AH, Breedveld FC et al Early versus delayed treatment in patients with recent onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001; 111 (6) 446-51
    CrossrefPubMedSearch in Google Scholar
  • 3 Egsmose C, Lund B, Borg G, Petterson H, Berg E, Brodin U et al Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow up of a prospective double blind placebo controlled study. J Rheumatol. 1995; 22 (12) 2208-13
    PubMedSearch in Google Scholar
  • 4 Boers M, Verhieven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al Randomised comparison of combined step down prednisolone, methotrexate and sulfasalazine with sulfasalazine alone in early rheumatoid arthritis. Lancet. 1997; 350 (9074) 309-18
    CrossrefPubMedSearch in Google Scholar
  • 5 Mottonen T, Hannonen P, Leirisalo Repo M, Nissilä M, Kautiainen H, Korpela M et al Comparison of combined therapy with single-drug therapy in early rheumatoid arthritis. Lancet. 1999; 353 (9164) 1568-73
    CrossrefPubMedSearch in Google Scholar
  • 6 Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB.. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997; 36 (10) 1082-8
    CrossrefPubMedSearch in Google Scholar
  • 7 O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ et al Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996; 334 (20) 1287-91
    CrossrefPubMedSearch in Google Scholar
  • 8 O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ et al Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications. Results of a two year randomized, double blind, placebo controlled trial. Arthritis Rheum. 2002; 46 (5) 1164-70
    CrossrefPubMedSearch in Google Scholar
  • 9 Kremer JM, Kaye GI, Kaye NW, Ishak KG, Axiotis CA.. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Follow up over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum. 1995; 38 (9) 1194-203
    CrossrefPubMedSearch in Google Scholar
  • 10 Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum. 1996; 39 (5) 723-31
    CrossrefPubMedSearch in Google Scholar
  • 11 Maddison P, Kiely P, Kirkham B, Lawson T, Moots R, Proudfoot D et al Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology. 2005; 44 (3) 280-6
    CrossrefPubMedSearch in Google Scholar
  • 12 Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE et al Combination of leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol. 2004; 31 (8) 1521-31
    PubMedSearch in Google Scholar
  • 13 Choy EH, Smith C, Doré CJ, Scott DL.. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology. 2005; 44 (11) 1414-21
    CrossrefPubMedSearch in Google Scholar
  • 14 Raczkiewicz-Papierska A, Dudek A, Bachta A, Ttustochowicz M, Zawadyl B, Sutek M.. Leflunomide as a second choice drug in patients with rheumatoid arthritis. Pol Merkur Lekarski. 2007; 22 (132) 547-50
    PubMedSearch in Google Scholar
  • 15 Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI et al Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol. 2009; 38 (1) 11-4
    CrossrefPubMedSearch in Google Scholar
  • 16 Garrood T, Scott DL.. Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Bio Drugs. 2001; 15: 543-61
    PubMedSearch in Google Scholar
  • 17 Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M et al Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 1999; 42 (7) 1322-8
    CrossrefPubMedSearch in Google Scholar
  • 18 Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M et al Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulfasalazine and methotrexate compared with the single components. Ann RheumDis. 1999; 58 (4) 220-5
    PubMedSearch in Google Scholar
  • 19 Emery P, Breedfeld C, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B et al A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology. 2000; 39: 655-665
    CrossrefPubMedSearch in Google Scholar
  • 20 Arava, Leflunomide tablets (product nonograph). Laval (QC) Aventis Pharma Inc; 2001.
    PubMed
  • 21 The Europaean Agency for the Evaluation of Medicinal Products. EMEA issues public statement on leflunomide. Reactions Weekly. 2001; 844: 2-
    PubMedSearch in Google Scholar
  • 22 Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999; 159 (21) 2542-50
    CrossrefPubMedSearch in Google Scholar
  • 23 Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999; 353: 259-66
    CrossrefPubMedSearch in Google Scholar
  • 24 Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE et al Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002; 137 (9) 726-33
    CrossrefPubMedSearch in Google Scholar
  • 25 van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers JR.. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. DrugSaf. 2004; 27: 345-52
    PubMedSearch in Google Scholar
  • 26 Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel P.. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann Rheum Dis. 2005; 64 (1) 44-51
    PubMedSearch in Google Scholar